Imipramine pamoate is an oral capsule classified as a tricyclic antidepressant. The selected FDA label identifies its use as relief of depression symptoms. Understanding its safety information requires three distinctions: capsule-specific facts, reactions included because of similarities across tricyclic medicines, and older-adult evidence drawn from a different imipramine formulation.
If you are reading about an existing or proposed prescription, a long label can make very different kinds of information look equally certain. This article explains supplied extracts from the RemedyRepack imipramine pamoate record, application ANDA090444. It does not combine indications from other imipramine products or provide personal medication directions. The central question is what this particular document establishes, including what it cannot tell you about likely benefit, the cause of a symptom, or individual safety. Its accompanying Medication Guide adds important patient information but does not replace the product’s fuller interaction and adverse-reaction sections.
What is imipramine pamoate labeled to treat?
The selected capsule label states that imipramine pamoate is indicated for relief of symptoms of depression. That product-specific statement is distinct from the document roles explained in MVBH’s overview of medicine information and its guide to Medication Guides and serious risks.
The description identifies capsules for oral use and classifies the medicine as a tricyclic antidepressant. It expresses their imipramine pamoate contents in imipramine hydrochloride-equivalent amounts. This is a description of product strength, not a method for converting a prescription or evidence that capsules and hydrochloride tablets have identical labeling or are interchangeable. These distinctions come from the selected FDA labeling record.
The indication also uses the historical term “endogenous depression.” That wording should not become a self-identification category, a biological explanation for someone’s depression, or a rule for selecting this medicine. The selected indication does not list anxiety disorders, panic disorder, OCD, insomnia, pain, or bedwetting. That absence describes this record’s indication; it does not resolve why an individual received a prescription or judge whether that prescription is appropriate.
What does its adverse-reaction list actually establish?
The list establishes concerns to consider, not a ranked forecast of what will happen. MVBH’s explanation of serious-risk language and overview of professional and patient medicine information provide context for reading that distinction.
Crucially, the adverse-reaction section says it includes a few reactions not reported with this specific drug because of similarities among tricyclic antidepressants. Consequently, every entry cannot be described as an observation specific to imipramine pamoate. Nor does the list establish that the medicine caused a particular person’s symptoms. The FDA record’s opening qualification applies throughout that discussion.
Selected listed effects concern different functions. The following groups explain their subjects, not their frequency or seriousness in an individual:
- Mouth and vision: dry mouth and blurred vision concern different physical functions, even though both appear under anticholinergic effects.
- Bowel and bladder: constipation, urinary retention, and delayed urination concern difficulty moving stool or emptying the bladder.
- Alertness and energy: drowsiness, dizziness, weakness, and fatigue describe different experiences rather than one interchangeable symptom.
- Weight and sexual function: weight gain or loss, increased or decreased sexual desire, and impotence are listed without incidence estimates in this extract.
A label entry can help name a concern without explaining its cause or likelihood. Calling these the “most common” effects would go beyond the supplied evidence.
Which physical safety concerns need careful interpretation?
Bowel, bladder, and vision effects are separate from blood-pressure and heart-related concerns. Reading patient medicine information alongside serious-risk explanations helps keep those categories distinct rather than treating every physical symptom as one type of reaction.
The cardiovascular list includes blood-pressure drops on standing, high blood pressure, rapid heartbeat, palpitations, and rhythm or conduction problems. Palpitations concern awareness of the heartbeat; conduction concerns the heart’s electrical signaling. Separately, the label contraindicates use during acute recovery after a heart attack. These are different statements with different purposes, not a symptom-based way to clear yourself for treatment. See the selected label’s cardiovascular and contraindication passages.
The Medication Guide also names low blood sodium, with greater risk in older people. Its described symptoms include headache, weakness or unsteadiness, confusion, trouble concentrating or thinking, and memory problems. These descriptions do not diagnose low sodium. The guide directs readers to tell their healthcare provider about low sodium during treatment; it does not make a general article a basis for changing food or fluid intake.
Eye pain, changes in vision, and swelling or redness in or around the eye receive separate attention. The adverse-reaction section also includes postmarketing reports of angle-closure glaucoma, without a reliably estimated frequency. These concerns should not be collapsed into ordinary blurred vision. The Medication Guide and adverse-reaction passages support professional medical advice about side effects, not home diagnosis or treatment. Serious physical symptoms need prompt medical evaluation.
What does the label say about mood and behavior changes?
The boxed warning identifies an increased risk of suicidal thinking and behavior in young adults in short-term antidepressant studies compared with placebo. Its relevance is not limited to understanding a document: Medication Guide risk information complements, rather than replaces, the fuller medicine information for professionals and patients.
The warning separately calls for close attention to worsening symptoms, suicidality, and unusual behavior at every treated adult age. The age-related study finding does not mean that changes in an older adult can be dismissed. Depression itself also carries suicide risk. These distinctions appear in the selected boxed warning.
The record lists agitation, restlessness, insomnia, hypomania, and confusional states. These are distinct concerns, not interchangeable names for one condition. A change in sleep or activity does not by itself establish a diagnosis. The Medication Guide directs readers to call a healthcare provider right away about new, worsening, or concerning mood and behavior changes, including suicidal thoughts.
For immediate danger or a life-threatening emergency, call 911. For suicide or crisis support, call or text 988, as described by NIMH. Crisis support does not replace medical evaluation of a serious physical reaction.
Why do its interactions involve more than antidepressants?
Interactions can change drug exposure or intensify particular effects, and some involve medicines used outside mental health care. MVBH’s medicine-information overview explains where interaction details fit, while its Medication Guide explanation clarifies why a patient guide is not the whole product document.
One important passage concerns CYP2D6, an enzyme involved in drug metabolism. Reduced activity can result in higher-than-expected tricyclic antidepressant concentrations. Certain medicines can inhibit that activity, meaning a person who previously appeared stable can develop toxicity after an interacting medicine is added. The record names SSRIs such as fluoxetine, sertraline, and paroxetine, while noting that their degree of inhibition varies. It also names cimetidine, showing why this issue is not restricted to antidepressant combinations. These facts come from the selected interaction section.
Other concerns are different in kind. They cannot all be explained as one medicine raising another medicine’s concentration:
- Additional anticholinergic effects: other medicines with these effects can intensify bowel, bladder, and related concerns.
- Central nervous system depression: the label warns that imipramine pamoate can enhance depressant effects, including those of alcohol.
- Blood-pressure and related effects: the record addresses blood-pressure-lowering agents and sympathomimetic ingredients found in some other preparations.
- MAOI contraindications: the label identifies combinations associated with increased serotonin-syndrome risk, including psychiatric MAOIs, linezolid, and intravenous methylene blue.
The interaction and contraindication passages do not create a safe-combination list. A medicine’s absence from this short explanation does not establish compatibility. This article provides no switching intervals, testing recommendations, or combination-management instructions.
What are the older-adult and pregnancy evidence limits?
The older-adult passage draws on studies of hydrochloride tablets, while the pregnancy passage describes unresolved risk. Both require the product and evidence distinctions discussed in understanding medicine information and interpreting serious-risk documents.
Specifically, the geriatric section discusses studies of Tofranil imipramine hydrochloride tablets, not dedicated studies of this pamoate capsule product. The cited older-adult studies lacked a younger comparison, and the original tablet studies included insufficient older participants to determine whether responses differed. Although the passage reports no identified response differences in postmarketing experience, that is not proof of equal response or safety. See the selected geriatric passage.
That evidence limitation is separate from listed concerns involving confusion, falls, and low sodium. The adverse-reaction section particularly notes confusional states in older people, and the Medication Guide identifies greater low-sodium risk in this population. Uncertainty about comparative studies does not cancel those safety concerns.
For pregnancy, the record states that no well-controlled studies in pregnant women establish imipramine’s fetal effects. It describes reports of congenital malformations without an established causal relationship, while stating that fetal risk cannot be excluded. A reported association is not proof of causation; missing causal proof is not proof of safety. Neither statement predicts an individual pregnancy outcome. The pregnancy passage does not support personal treatment recommendations here, and this article draws no breastfeeding conclusions.
Does its Medication Guide explain every product risk?
No. The guide explicitly identifies suicidal thoughts and actions with antidepressants as its focus, although it includes additional cautions. MVBH’s broader explanation of Medication Guides and overview of complementary medicine documents help explain why its presence does not make the other product sections unnecessary.
Different parts of this selected label answer different questions:
| Label component | Information it supplies | What it does not establish |
|---|---|---|
| Pamoate capsule description | Oral formulation and hydrochloride-equivalent strength description | Prescription interchangeability or a conversion method |
| Qualified adverse-reaction list | Listed concerns, including some drawn from tricyclic similarities | Product-specific incidence or individual causation |
| Geriatric tablet evidence | Findings concerning imipramine hydrochloride tablets | A pamoate-specific comparison establishing equal response by age |
| Antidepressant Medication Guide | Suicidality information and additional patient cautions | A complete account of product interactions and evidence limits |
These distinctions support understanding, not self-directed prescription changes. NIMH explains that treatment choices should reflect individual needs and medical circumstances under qualified professional guidance. MVBH is an adult outpatient mental health provider at 77 Elm St, Amesbury, Massachusetts. Routine service inquiries can go to 978-233-9597 or the contact page; this article does not establish an imipramine-specific service.
Source boundary: the FDA reference is the RemedyRepack record with set ID 76f412fd-f476-40c6-8aa7-9abced75c3e8, SPL ID 59799493-0088-734e-e063-6394a90a67ed, and effective time 20260820. That metadata is not an article publication date or proof of the latest label. This article uses the supplied extracts, not independently inspected complete warning or clinical-study sections.
Written by Tim Francis, SUD Content Specialist. This article is educational and does not diagnose, prescribe, or provide a medication-change plan.
Frequently asked questions
Are imipramine pamoate capsules the same as hydrochloride tablets?
They are different formulations. The selected FDA capsule description expresses imipramine pamoate contents in hydrochloride-equivalent amounts, but that does not establish identical labels or interchangeable prescriptions. The distinction also matters when reading the older-adult passage, which discusses studies of hydrochloride tablets rather than dedicated studies of this capsule product.
Does this capsule label list anxiety or insomnia as indications?
No. The selected FDA indication is relief of symptoms of depression. It does not list anxiety disorders, panic disorder, OCD, insomnia, pain, or bedwetting. That describes this particular record, not every imipramine product, and it does not determine the reason for or appropriateness of an individual prescription.
Was every listed reaction reported with imipramine pamoate?
No. The FDA adverse-reaction section explicitly includes a few reactions not reported with this specific drug because of similarities among tricyclic antidepressants. Its list therefore cannot be treated as entirely product-specific observations. It also does not provide a frequency ranking or establish that a listed reaction caused an individual’s symptoms.
Can medicines outside psychiatric care interact with it?
Yes. The selected FDA record names cimetidine among medicines that can affect drug exposure and separately discusses anticholinergic medicines, blood-pressure agents, and central nervous system depressants. It also identifies MAOI contraindications involving linezolid and intravenous methylene blue. These examples explain the breadth of concerns, not how to manage a combination.
Can the label predict whether this medicine will help me?
No. The selected FDA label identifies the product’s stated use, while its safety sections describe concerns and evidence limitations. Neither predicts your benefit or personal risk. Treatment decisions require individual medical context and qualified guidance. The label’s historical depression wording and formulation-specific details should not become self-diagnosis or medication-selection rules.
